Pfizer's Approach To Developing A Sustainable Business In Rare Disease R&D
By Rob Wright, Chief Editor, Life Science Leader magazine
Driving down Route 422 a few miles away from Pfizer’s Specialty Care Business Unit headquarters in the eastern Pennsylvania town of Collegeville, you might notice the remnants of a dilapidated farm. Past the rotted out, collapsing walls of the barn, you can still see the faded white top of a silo that once was used to store and isolate one type of grain from another. The image serves as a grim reminder for Pfizer employees Andrew Callos and Kevin Lee that in order to avoid a similar fate, their two business units, commercial operations and rare disease R&D, cannot operate in “silos” but must collaborate.